Literature DB >> 10828031

Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells.

V Russo1, D Zhou, C Sartirana, P Rovere, A Villa, S Rossini, C Traversari, C Bordignon.   

Abstract

In an attempt to transduce monocyte-derived dendritic cells (DCs) by a retroviral vector coding for a cell surface marker, we were confronted by the observation of high transfer of the surface molecule in the absence of vector proviral DNA in the treated cells. Indeed, DCs acquired the surface marker by a mechanism independent of the vector machinery, requiring cell-to-cell contact and involving transfer of lipids and a variety of intact membrane proteins. Most important, this property of DCs also includes acquisition of foreign human leukocyte antigen (HLA) molecules. Consequently, DCs become immunological hybrids as they display their own and foreign HLA molecules. The newly acquired HLA is fully functional because it allows recognition by allo-specific T lymphocytes and the binding and presentation of antigen peptides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828031

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Autologous apoptotic T cells interact with dendritic cells, but do not affect their surface phenotype or their ability to induce recall immune responses.

Authors:  P J Newton; I V D Weller; D R Katz; B M Chain
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 2.  Antigen presentation in the thymus for positive selection and central tolerance induction.

Authors:  Ludger Klein; Maria Hinterberger; Gerald Wirnsberger; Bruno Kyewski
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

Review 3.  Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer.

Authors:  Furong Zeng; Adrian E Morelli
Journal:  Semin Immunopathol       Date:  2018-03-28       Impact factor: 9.623

4.  Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs.

Authors:  Z Wang; S J Divito; W J Shufesky; T Sumpter; H Wang; O A Tkacheva; W Wang; C Liu; A T Larregina; A E Morelli
Journal:  Am J Transplant       Date:  2012-04-14       Impact factor: 8.086

5.  Trypanosoma cruzi invasion is associated with trogocytosis.

Authors:  Shankar Mukherjee; Aparna Mukhopadhyay; Grasiella Andriani; Fabiana Simão Machado; Anthony W Ashton; Huan Huang; Louis M Weiss; Herbert B Tanowitz
Journal:  Microbes Infect       Date:  2014-11-04       Impact factor: 2.700

6.  Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation.

Authors:  Jose Marino; Mohamed H Babiker-Mohamed; Patrick Crosby-Bertorini; Joshua T Paster; Christian LeGuern; Sharon Germana; Reza Abdi; Mayuko Uehara; James I Kim; James F Markmann; Georges Tocco; Gilles Benichou
Journal:  Sci Immunol       Date:  2016-07-14

7.  Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.

Authors:  O Manches; G Lui; J P Molens; J J Sotto; L Chaperot; J Plumas
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

8.  Alloprimed CD8(+) T cells regulate alloantibody and eliminate alloprimed B cells through perforin- and FasL-dependent mechanisms.

Authors:  J M Zimmerer; T A Pham; C L Wright; K J Tobin; P B Sanghavi; S M Elzein; V M Sanders; G L Bumgardner
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

Review 9.  Extracellular vesicles in allograft rejection and tolerance.

Authors:  Gilles Benichou; Mengchuan Wang; Kaitlan Ahrens; Joren C Madsen
Journal:  Cell Immunol       Date:  2020-02-08       Impact factor: 4.868

10.  HIV-1 infection of DC: evidence for the acquisition of virus particles from infected T cells by antigen uptake mechanism.

Authors:  Narasimhan J Venkatachari; Sean Alber; Simon C Watkins; Velpandi Ayyavoo
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.